Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis

Table 2 Comparison of adverse reactions of immunotherapy in patients with advanced gastric cancer with liver metastasis and no liver metastasis grade 1-2, n (%)

Adverse reaction	Liver metastasis (n = 20)	No liver metastasis grade 1-2 (n = 28)	χ2	P value
All events related to treatment	10 (50.0)	13 (46.4)	0.060	0.999
Nausea	7 (35.0)	7 (25.0)	0.565	0.528
Diarrhea	6 (30.0)	8 (29.0)	0.012	0.999
Fever	5 (25.0)	8 (29.0)	0.075	0.999
Peripheral neuropathy	4 (20.0)	6 (21.0)	0.014	0.999
Vomit	7 (35.0)	8 (29.0)	0.224	0.755
Fatigue	5 (25.0)	8 (29.0)	0.075	0.999
Anaemia	6 (30.0)	6 (21.0)	0.457	0.520
Anorexia	5 (25.0)	5 (18.0)	0.361	0.721
Rash	3 (15.0)	4 (14.0)	0.005	0.999
Thrombopenia	4 (20.0)	4 (14.0)	0.274	0.703
Abnormal liver function	5 (25.0)	4 (14.0)	0.879	0.460
Leukopenia	4 (20.0)	5 (18.0)	0.035	0.999